Haeberlein SB, Gheuens S, Chen T, et al. Aducanumab 36-month data from PRIME: a randomized, double-blind, placebocontrolled phase 1b study in patients with prodromal or mild Alzheimer’s disease. AAN 2018, S2.004.
Primaire auto-immuun hemolytische anemie geassocieerd met ischemisch CVA
feb 2024 | Benigne hematologie, Neuro-vasculair